查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球膀胱癌市場評估：按類型、方式、最終用戶、地區、機會、預測（2017-2031）
市場調查報告書
商品編碼
1417600

全球膀胱癌市場評估：按類型、方式、最終用戶、地區、機會、預測（2017-2031）

Bladder Cancer Market Assessment, By Types, By Modality, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球膀胱癌市場規模預計到2023年將達到45.1億美元，到2031年將達到68.1億美元，2024-2031年預測期間複合年增長率為5.28%。眾多原因正在推動全球膀胱癌市場的發展，包括膀胱癌盛行率的增加、老年人口的增加、診斷和治療技術的進步、政府措施以及研發資金的增加。膀胱癌盛行率的增加是全球膀胱癌市場的主要驅動因素。

膀胱癌是全球第十大常見癌症。這可能是由於多種因素造成的，包括人口老化和環境致癌物暴露的增加。隨著世界人口老化，膀胱癌的風險增加，增加了對診斷和治療方案的需求。醫療基礎設施的進步和可近性的提高正在促進全球膀胱癌市場的成長。更好地獲得醫療服務、更高品質的護理和先進的設施可以使膀胱癌患者更早發現並獲得更好的結果。

影像技術、非侵入性尿液檢測和分子診斷方面的創新正在徹底改變早期檢測和監測，從而改善患者的治療結果。菸草消費和接觸工業化學品的增加在膀胱癌的發展中發揮重要作用，迅速增加了全球膀胱癌市場的需求。市場正在見證可提高治療效果並增強患者體驗的技術進步，包括微創手術技術、機器人輔助手術和精準醫療。政府措施和研究資金正在促進市場擴張。膀胱癌研究（包括臨床試驗和藥物開發）的投資增加正在推動創新並帶來新的治療方法和診斷工具。

膀胱癌盛行率增加

膀胱癌發生率和盛行率的增加在擴大全球膀胱癌市場方面發揮重要作用。膀胱癌是世界上第六大常見癌症，有明顯的性別差異，在男性中排名第十，在女性中排名第十七。這種高盛行率是由許多因素造成的，包括老化、接觸環境致癌物的增加以及個人生活方式的選擇。隨著膀胱癌患者數量持續增加，對先進診斷技術、治療和醫療照護的需求不斷增加。需求的激增推動了膀胱癌市場的研究、創新和投資，以實現早期檢測、更先進的治療和加強患者護理。

技術進步

最近的技術進步對於全球膀胱癌市場的發展至關重要。這些醫療創新徹底改變了膀胱癌的診斷、治療和監測方式。這些創新包括微創手術技術的發展、引入機器人輔助手術以提高精確度以及引入個人化醫療方法。這些突破透過減少侵入性和加速康復來提高治療效果和整體患者體驗。此外，最先進的影像方式和診斷工具有助於早期檢測，是改善膀胱癌預後的關鍵因素。這些技術進步處於塑造全球膀胱癌市場成長和前景的最前沿。

政府的努力

世界各國政府積極參與各種舉措，包括與各種組織建立夥伴關係，以提高對膀胱癌的認識。這些努力包括開展公共衛生運動、實施教育計畫和支持研究工作。透過優先提高意識，政府和合作組織旨在教育大眾了解膀胱癌的風險因素、症狀、早期檢測和可用於治療的資源。這提高了我們對這種疾病的了解，並激勵我們採取預防措施並及時就醫。提高意識最終將導致早期診斷、改善治療結果並減輕醫療保健系統的負擔，凸顯了這項全球努力對抗膀胱癌的重要性。

本報告研究和分析了全球膀胱癌市場，提供市場規模和預測、市場動態、主要參與者趨勢和前景等。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章全球膀胱癌市場展望（2017-2031）

  • 市場規模及預測
    • 金錢數額
    • 數量
  • 按類型
    • 尿路上皮癌
    • 腺癌
    • 鱗狀細胞癌
    • 其他
  • 按方式
    • 診斷
    • 治療
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 專科診所
    • 藥店
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 市場佔有率：依公司劃分（2023 年）

第五章全球膀胱癌市場展望：按地區（2017-2031）

  • 北美
    • 市場規模及預測
    • 按類型
    • 按方式
    • 按最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第六章 市場測繪（2023）

  • 按類型
  • 按方式
  • 按最終用戶
  • 按地區

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第九章 監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監管審批
  • 創新/新技術

第十章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT分析（5家進入市場的公司）
  • 專利分析（如果適用）

第11章價格分析

第十二章案例研究

第十三章 主要公司展望

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Johnson & Johnson Innovative Medicine
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Ferring B.V.
  • Seagen Inc.
  • Asieris Pharmaceuticals
  • Bristol-Myers Squibb Company

第十四章 戰略建議

第十五章 關於我們公司、免責聲明

Product Code: MX10894

Global bladder cancer market size was valued at USD 4.51 billion in 2023, which is expected to reach USD 6.81 billion in 2031, with a CAGR of 5.28% for the forecast period between 2024 and 2031. Numerous factors are propelling the global bladder cancer market, such as the increasing prevalence of bladder cancer, the growing geriatric population, technological advancements in diagnostic and treatment methodologies, government initiatives, and increasing funding for research and development. The rising prevalence of bladder cancer is a significant factor driving the global bladder cancer market.

Bladder cancer ranks as the 10th most common cancer worldwide. It can be attributed to various factors, including an aging population and increased exposure to environmental carcinogens. As the global population ages, the risk of bladder cancer increases, creating a growing demand for diagnostic and treatment options. Advancements in healthcare infrastructure and growing accessibility are contributing to the growth of global bladder cancer market. Better access to healthcare services, higher quality of care, and advanced facilities can lead to early detection and better outcomes for bladder cancer patients.

Innovations in imaging technologies, non-invasive urine tests, and molecular diagnostics have revolutionized early detection and monitoring, leading to better patient outcomes. Increasing consumption of tobacco and increased exposure to industrial chemicals play a significant role in bladder cancer development, surging the demand for the global bladder cancer market. The market is witnessing technological advancements such as minimally invasive surgical techniques, robotic-assisted surgery, and precision medicine which improves the effectiveness of treatments and enhance patient experiences. Government initiatives and research funding are contributing to market expansion. Growing investment in bladder cancer research, including clinical trials and drug development, is expediting innovation and introducing new therapies and diagnostic tools.

Rising Prevalence of Bladder Cancer

The increasing incidence and prevalence of bladder cancer play a significant role in the expansion of the global bladder cancer market. Bladder cancer, recognized as the 6th most widespread form of cancer worldwide, presents a distinct gender divide, with it being the 10th most common cancer among men and the 17th most prevalent among women. The high prevalence is shaped by a multitude of factors, including the aging population, heightened exposure to environmental carcinogens, and individual lifestyle choices. As the number of bladder cancer cases continues to rise, there is an increasing demand for advanced diagnostic techniques, treatment modalities, and healthcare provisions. The surge in demand stimulates research, fosters innovation, and attracts investments in the bladder cancer market, geared towards enhancing early detection, more advanced therapies, and increased patient care.

Technological Advancements

Recent technological advancements are pivotal in driving the global bladder cancer market forward. These medical technology innovations have revolutionized how bladder cancer is diagnosed, treated, and monitored. They encompass the creation of less invasive surgical techniques, the incorporation of precision-enhancing robotic-assisted surgery, and the introduction of personalized medicine approaches. These breakthroughs enhance treatments' efficacy and the overall patient experience by reducing invasiveness and speeding up recovery. Additionally, state-of-the-art imaging methods and diagnostic tools are facilitating early detection, which is a critical factor in enhancing bladder cancer outcomes. These technological advancements are at the forefront of shaping the growth and potential of the global bladder cancer market. UC San Diego Health became the first healthcare system to provide a new technology that uses white light, blue light, and an imaging dye that causes cancer cells to glow fluorescent pink to identify and monitor bladder cancer in both clinic and operating room settings in San Diego.

Government Initiatives

Governments around the globe are actively involved in various initiatives such as partnerships with various organizations to increase awareness about bladder cancer. These initiatives encompass the deployment of public health campaigns, the implementation of educational programs, and the provision of support for research endeavors. By prioritizing awareness, governments and collaborating organizations aim to educate the public about risk factors, symptoms, early detection, and the available resources for managing bladder cancer. It fosters a deeper understanding of the disease and motivates individuals to embrace preventive measures and seek prompt medical attention. Enhanced awareness can ultimately result in earlier diagnoses, improved treatment outcomes, and a decreased burden on healthcare systems, underscoring the significance of these global initiatives in the battle against bladder cancer.

Fight Bladder Cancer UK, a proactive national organization driven by patients, hosted a parliamentary event in May 2023. Fight Bladder Cancer places a strong emphasis on the significance of timely screening, urging people to remain vigilant regarding possible symptoms and promptly consult a healthcare professional. It involves raising awareness among healthcare practitioners about identifying early indicators and implementing effective diagnostic procedures.

Transitional Cell Carcinoma Dominated the Market

The global bladder cancer market is witnessing a surging need for treatments custom-tailored for transitional cell carcinoma (TCC). This type of bladder cancer comprises a substantial share of all bladder cancer cases. The growing demand can be ascribed to multiple factors, including the rising incidence of transitional cell carcinoma, advancements in diagnostic techniques enabling more precise TCC detection, and an increased emphasis on individualized treatment strategies. As awareness and comprehension of the distinctive attributes and treatment requisites of TCC broaden, pharmaceutical companies and healthcare providers are allocating resources to research and therapies that address the specific needs of this subset of bladder cancer patients.

In April 2023, the Japanese multinational pharmaceutical company Astellas Pharma disclosed that Food and Drug Administration (FDA) had issued accelerated approval for Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for the initial treatment of adults with locally advanced or metastatic transitional cell carcinoma who are not suitable candidates for cisplatin-containing chemotherapy.

Future Market Scenario

The outlook for the global bladder cancer market appears highly promising, owing to its exceptional opportunities. Bladder cancer ranks amongst the most prevalent cancers globally, rendering it a central focus for pharmaceutical and biotechnology firms. The increasing incidence of bladder cancer, influenced by factors such as an aging population, environmental factors, and evolving lifestyles, fuels a rising demand for innovative diagnostic tools and therapeutic interventions.

Furthermore, significant technological advancements have reshaped the landscape such as introduction of new treatments, precision medicine, and less invasive surgical methods that enhance patient outcomes. Strategic alliances and acquisitions among major industry players further amplify the market's growth potential, which stimulates collaborative research and development endeavors. With an expanding awareness and comprehension of bladder cancer, the market is primed to make substantial strides in the pursuit of more efficacious treatments, early detection, and enhanced patient care.

Key Players Landscape and Outlook

In the global bladder cancer market, prominent pharmaceutical and biotechnology firms are progressively entering into strategic alliances to seize the extensive prospects. These partnerships allow these companies to merge their knowledge, resources, and research endeavors, with the goal of creating innovative diagnostic tools, therapies, and treatment solutions. Moreover, these collaborative efforts facilitate the exchange of expertise and cutting-edge technologies, which are vital in addressing the intricacies of bladder cancer. By consolidating their capabilities, these companies aspire to expedite the development of pharmaceuticals, improve patient care, and meet the unfulfilled medical requirements in the domain. Ultimately, these partnerships empower the industry to cater to the escalating demand more effectively for bladder cancer treatments and diagnostic methods.

In October 2023, the European Union approved the acquisition of the biotechnology company Seagen, which specializes in innovative cancer treatments by Pfizer. The deal, valued at USD 43 billion, is set to broaden Pfizer's range of bladder cancer medications through the incorporation of Seagen's therapies.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Bladder Cancer Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Types
    • 4.2.1. Urothelial Carcinoma
    • 4.2.2. Adenocarcinoma
    • 4.2.3. Squamous Cell Carcinoma
    • 4.2.4. Others
  • 4.3. By Modality
    • 4.3.1. Diagnosis
      • 4.3.1.1. Cytology
      • 4.3.1.2. Cystoscopy
      • 4.3.1.3. MRI Scan
      • 4.3.1.4. CT Scan
    • 4.3.2. Treatment
      • 4.3.2.1. Surgery
      • 4.3.2.2. Radiation Therapy
      • 4.3.2.3. Radiopharmaceuticals
      • 4.3.2.4. Transurethral Bladder Tumour Resection
      • 4.3.2.5. Chemotherapy
      • 4.3.2.6. Immunotherapy
      • 4.3.2.7. Gene Therapy
      • 4.3.2.8. Cryotherapy
      • 4.3.2.9. High-Intensity Focused Ultrasound
      • 4.3.2.10. Targeted Therapy
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Specialty Clinics
    • 4.4.4. Pharmacies
    • 4.4.5. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. South America
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Bladder Cancer Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Types
      • 5.1.2.1. Urothelial Carcinoma
      • 5.1.2.2. Adenocarcinoma
      • 5.1.2.3. Squamous Cell Carcinoma
      • 5.1.2.4. Others
    • 5.1.3. By Modality
      • 5.1.3.1. Diagnosis
      • 5.1.3.1.1. Cytology
      • 5.1.3.1.2. Cystoscopy
      • 5.1.3.1.3. MRI Scan
      • 5.1.3.1.4. CT Scan
      • 5.1.3.2. Treatment
      • 5.1.3.2.1. Surgery
      • 5.1.3.2.2. Radiation Therapy
      • 5.1.3.2.3. Radiopharmaceuticals
      • 5.1.3.2.4. Transurethral Bladder Tumour Resection
      • 5.1.3.2.5. Chemotherapy
      • 5.1.3.2.6. Immunotherapy
      • 5.1.3.2.7. Gene Therapy
      • 5.1.3.2.8. Cryotherapy
      • 5.1.3.2.9. High-Intensity Focused Ultrasound
      • 5.1.3.2.10. Targeted Therapy
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Ambulatory Surgical Centers
      • 5.1.4.3. Specialty Clinics
      • 5.1.4.4. Pharmacies
      • 5.1.4.5. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size and Forecast
      • 5.1.5.1.1. Value
      • 5.1.5.1.2. Volume
      • 5.1.5.2. By Types
      • 5.1.5.2.1. Urothelial Carcinoma
      • 5.1.5.2.2. Adenocarcinoma
      • 5.1.5.2.3. Squamous Cell Carcinoma
      • 5.1.5.2.4. Others
      • 5.1.5.3. By Modality
      • 5.1.5.3.1. Diagnosis
      • 5.1.5.3.1.1. Cytology
      • 5.1.5.3.1.2. Cystoscopy
      • 5.1.5.3.1.3. MRI Scan
      • 5.1.5.3.1.4. CT Scan
      • 5.1.5.3.2. Treatment
      • 5.1.5.3.2.1. Surgery
      • 5.1.5.3.2.2. Radiation Therapy
      • 5.1.5.3.2.3. Radiopharmaceuticals
      • 5.1.5.3.2.4. Transurethral Bladder Tumour Resection
      • 5.1.5.3.2.5. Chemotherapy
      • 5.1.5.3.2.6. Immunotherapy
      • 5.1.5.3.2.7. Gene Therapy
      • 5.1.5.3.2.8. Cryotherapy
      • 5.1.5.3.2.9. High-Intensity Focused Ultrasound
      • 5.1.5.3.2.10. Targeted Therapy
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Ambulatory Surgical Centers
      • 5.1.5.4.3. Specialty Clinics
      • 5.1.5.4.4. Pharmacies
      • 5.1.5.4.5. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Types
  • 6.2. By Modality
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Astellas Pharma Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. AstraZeneca plc
  • 13.3. Johnson & Johnson Innovative Medicine
  • 13.4. Bayer AG
  • 13.5. Merck & Co., Inc.
  • 13.6. Pfizer, Inc.
  • 13.7. Ferring B.V.
  • 13.8. Seagen Inc.
  • 13.9. Asieris Pharmaceuticals
  • 13.10. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 4. Global Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 5. Global Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Bladder Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 10. North America Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 11. North America Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 16. United States Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 17. United States Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 21. Canada Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 22. Canada Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 26. Mexico Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 27. Mexico Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 31. Europe Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 32. Europe Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 37. Germany Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 38. Germany Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 42. France Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 43. France Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 47. Italy Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 48. Italy Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 52. United Kingdom Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 53. United Kingdom Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 57. Russia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 58. Russia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 62. Netherlands Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 63. Netherlands Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 67. Spain Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 68. Spain Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 72. Turkey Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 73. Turkey Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 77. Poland Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 78. Poland Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 82. South America Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 83. South America Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 88. Brazil Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 89. Brazil Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 93. Argentina Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 94. Argentina Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 98. Asia-Pacific Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 99. Asia-Pacific Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 104. India Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 105. India Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 109. China Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 110. China Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 114. Japan Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 115. Japan Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 119. Australia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 120. Australia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 124. Vietnam Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 125. Vietnam Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 129. South Korea Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 130. South Korea Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 134. Indonesia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 135. Indonesia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 139. Philippines Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 140. Philippines Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 144. Middle East & Africa Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 145. Middle East & Africa Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 150. Saudi Arabia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 151. Saudi Arabia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 155. UAE Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 156. UAE Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 160. South Africa Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 161. South Africa Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023